ReviewBMJ global health2020
Ending TB in Southeast Asia: current resources are not enough.
Review in BMJ global health, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- A model for the epidemiological impact of tuberculosis policy options.Bulletin of the World Health Organization · 2026Article
- Risk factors of multi-drug-resistant tuberculosis among tuberculosis patients in Bagmati Province, Nepal: a matched case-control study.BMC infectious diseases · 2026Article
- From DOTS to DOST: a new framework for TB elimination in India.The Lancet regional health. Southeast Asia · 2026Review
- Global, regional, and national burden of tuberculosis, 1990-2050: a systematic comparative analysis based on retrospective cross-sectional of GBD 2021 and WHO surveillance systems.International journal of surgery (London, England) · 2026Article
- ThemedRxiv : the preprint server for health sciences · 2025Article
- Patient and health system delays in the diagnosis and treatment of tuberculosis in Gandaki, Nepal.PLOS global public health · 2025Article
- Further analysis of tuberculosis in eight high-burden countries based on the Global Burden of Disease Study 2021 data.Infectious diseases of poverty · 2024Article
- Long-term exposure to ambient fine particulate matter (PMBMJ open · 2024Article
- Ending TB in South-East Asia: flagship priority and response transformation.The Lancet regional health. Southeast Asia · 2023Review
- Meeting the 2030 END TB goals in the wake of COVID-19: A modelling study of countries in the USAID TB portfolio.PLOS global public health · 2023Article
- Construction and application of tuberculosis medical and nursing integration cooperation model.Public health nursing (Boston, Mass.) · 2023Article
- The challenges of ascites management: An Indian perspective.Clinical liver disease · 2022Review
- Article
- Engaging with the private healthcare sector for the control of tuberculosis in India: cost and cost-effectiveness.BMJ global health · 2021Article
- Childhood Tuberculosis: An Under Prioritized Disease in Nepal.JNMA; journal of the Nepal Medical Association · 2021Article
- An Integrative Network Approach to Identify Common Genes for the Therapeutics in Tuberculosis and Its Overlapping Non-Communicable Diseases.Frontiers in pharmacology · 2021Article
- Management of Portal Hypertension.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The Southeast Asia Region continues to battle tuberculosis (TB) as one of its most severe health and development challenges. Unless there is a substantial increase in investments for TB prevention, diagnosis, care and treatment, there will be catastrophic effects for the region. The uncontrolled TB burden impacts socioeconomic development and increase of drug resistance in the region. Based on epidemiological inputs from a mathematical model, a costing analysis estimates that the desired targets of ending TB are achievable with additional interventions, and critical thresholds require an increase in spending by almost double the current levels. The data source for financial allocation to TB programmes is the report submitted by countries to WHO, while projections are based on modelling. The model accounts for funding needs for all strategies based on published data and accounts for programme and patient costs. This paper delineates the resource needs, availability and gaps of ending TB in the region. It is estimated that close to US$2 billion per year are needed in the region for TB-related activities for a meaningful bending of the incidence curve towards ending TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.